Clinical Trial Update: A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors. [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 study evaluating the safety and dosing of JNJ-26854165 in patients with advanced or refractory solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• JNJ-26854165

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Neoplasms | Phase 1 | Status: COMPLETED